Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons — 43 U.S. Jurisdictions, July 31–October 1, 2022

Simple item page
dc.contributor.authorPayne, Amanda B.
dc.contributor.authorRay, Logan C.
dc.contributor.authorCole, Matthew M.
dc.contributor.authorCanning, Michelle
dc.contributor.authorHouck, Kennedy
dc.contributor.authorShah, Hazel J.
dc.contributor.authorFarrar, Jennifer L.
dc.contributor.authorLewis, Nathaniel M.
dc.contributor.authorFothergill, Amy
dc.contributor.authorWhite, Elizabeth B.
dc.contributor.authorFeldstein, Leora R.
dc.contributor.authorRoper, Lauren E.
dc.contributor.authorLee, Florence
dc.contributor.authorKriss, Jennifer L.
dc.contributor.authorSims, Emily
dc.contributor.authorSpicknall, Ian H.
dc.contributor.authorNakazawa, Yoshinori
dc.contributor.authorGundlapalli, Adi V.
dc.contributor.authorShimabukuro, Tom
dc.contributor.authorCohen, Adam L.
dc.contributor.authorHonein, Margaret A.
dc.contributor.authorMermin, Jonathan
dc.contributor.authorPayne, Daniel C.
dc.contributor.departmentPediatrics, School of Medicine
dc.date.accessioned2025-03-03T16:48:59Z
dc.date.available2025-03-03T16:48:59Z
dc.date.issued2022
dc.description.abstractWhat is already known about this topic? Real-world data on the magnitude and durability of protection by JYNNEOS vaccine against monkeypox (mpox) remain limited. What is added by this report? Among JYNNEOS vaccine-eligible men aged 18–49 years in 43 U.S. jurisdictions, mpox incidence among unvaccinated persons was 9.6 times as high as that among persons who had received 2 vaccine doses and 7.4 times as high as that among persons who had received only the first dose. Preliminary evidence indicates no difference in protection between subcutaneous and intradermal administration routes. What are the implications for public health practice? Although further study is needed to determine the magnitude and durability of protection, evidence indicates that JYNNEOS vaccination provides protection against mpox. Vaccine-eligible persons should complete the 2-dose vaccination series.
dc.eprint.versionFinal published version
dc.identifier.citationPayne AB, Ray LC, Cole MM, et al. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons — 43 U.S. Jurisdictions, July 31–October 1, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1560–1564. DOI: http://dx.doi.org/10.15585/mmwr.mm7149a5
dc.identifier.urihttps://hdl.handle.net/1805/46189
dc.language.isoen_US
dc.publisherCenter for Disease Control
dc.relation.isversionof10.15585/mmwr.mm7149a5
dc.relation.journalMMWR: Morbidity and Mortality Weekly Report
dc.rightsCC0 1.0 Universalen
dc.rights.urihttps://creativecommons.org/publicdomain/zero/1.0
dc.sourcePublisher
dc.subjectJYNNEOS vaccine
dc.subjectMonkeypox
dc.subjectVaccine efficacy
dc.titleReduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons — 43 U.S. Jurisdictions, July 31–October 1, 2022
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Payne2022Reduced-CC0.pdf
Size:
275.87 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Open Access Policy Articles